| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
|
Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
|
Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
|
Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG; Zhang X.; Zhang X.;Chih-Hsin Yang;Ahn M.-J;Kim D.-W;Rabbie S;Bai Y;Yin X;Xu Y;Cheng Z;Zhang L;Chen K;Wang Y;Guo Q;Yang Z; Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
|
Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG; Zhang X.; Zhang X.;Chih-Hsin Yang;Ahn M.-J;Kim D.-W;Rabbie S;Bai Y;Yin X;Xu Y;Cheng Z;Zhang L;Chen K;Wang Y;Guo Q;Yang Z; Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Scientific Advances in Thoracic Oncology 2016
|
Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Scientific Advances in Thoracic Oncology 2016
|
Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials
|
Jänne P.A; CHIH-HSIN YANG; Mitsudomi T; Johnson M; Cantarini M; Chih-Hsin Yang;J?nne P.A;Mitsudomi T;Johnson M;Cantarini M;Hodge R;Morabito A;Felip E;De Marinis F;Crin? L;Bazhenova L;Ahn M.-J;Shepherd F.A;Tsai C.-M;Goss G; Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials
|
Jänne P.A; CHIH-HSIN YANG; Mitsudomi T; Johnson M; Cantarini M; Chih-Hsin Yang;J?nne P.A;Mitsudomi T;Johnson M;Cantarini M;Hodge R;Morabito A;Felip E;De Marinis F;Crin? L;Bazhenova L;Ahn M.-J;Shepherd F.A;Tsai C.-M;Goss G; Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Osimertinib in patients with T790M mutation-positive, advanced non?�small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
|
Ahn M.-J;Tsai C.-M;Shepherd F.A;Bazhenova L;Sequist L.V;Hida T;Chih-Hsin Yang;Ramalingam S.S;Mitsudomi T;Jnne P.A;Mann H;Cantarini M;Goss G.; Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Osimertinib in patients with T790M mutation-positive, advanced non?�small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
|
Ahn M.-J;Tsai C.-M;Shepherd F.A;Bazhenova L;Sequist L.V;Hida T;Chih-Hsin Yang;Ramalingam S.S;Mitsudomi T;Jnne P.A;Mann H;Cantarini M;Goss G.; Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T02:45:31Z |
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non�Vsmall cell lung cancer
|
Wang L; Wu Y.-L; Lu S; Deng L; Ahn M.-J; Feng-Ming Hsu; Iscoe N; Hossain A; Puri T; Zhang P; Orlando M. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 國立成功大學 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn, M.-J.;Kim, D.-W.;Cho, B.C.;Kim, S.-W.;Lee, J.S.;Ahn, J.-S.;Kim, T.M.;Lin, C.-C.;Kim, H.R.;John, T.;Kao, S.;Goldman, J.W.;Su, W.-C.;Natale, R.;Rabbie, S.;Harrop, B.;Overend, P.;Yang, Z.;Yang, J.C.-H. |
